Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma
Abstract. The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I...
Main Authors: | Klaus Herfarth, Peter Borchmann, Sven Schnaidt, Karin Hohloch, Volker Budach, Marianne Engelhard, Andreas Viardot, Rita Engenhart-Cabillic, Ulrich Keller, Gabriele Reinartz, Hans-Theodor Eich, Mathias Witzens-Harig, Clemens F. Hess, Bernd Dörken, Jan Dürig, Thomas Wiegel, Wolfgang Hiddemann, Eva Hoster, Christiane Pott, Martin Dreyling |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000160 |
Similar Items
-
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma– a risk stratified analysis of the GHSG HD17 trial
by: Michael Oertel, et al.
Published: (2023-05-01) -
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas
by: Heike Horn, et al.
Published: (2022-09-01) -
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
by: Mathias Witzens-Harig, et al.
Published: (2021-10-01) -
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
by: Friederike Braulke, et al.
Published: (2022-12-01) -
P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
by: Michael Oertel, et al.
Published: (2022-10-01)